Ca2+ sensitizer, pimobendan, attenuates myocardial injury in low-flow ischemic but not in total ischemic hearts

H. Hasegawa, M. Tani, Y. Honma, K. Tamaki, K. Yamamura, Michiyo Takayama, Y. Ebihara

Research output: Contribution to journalArticle

Abstract

Whether Ca2+ sensitizer is beneficial in cases of ischemic myocardium is still controversial. We examined the effect of pimobendan on ischemic-reperfusion injury. Isolated SD rat hearts were subjected to 30 minutes of low-flow ischemia (LF) or 25 minutes of total ischemia (TI) after 10 minutes of preperfusion, and were followed by 30 minutes of reperfusion. In another two groups we used 50μM of pimobendan during LF (LFp) or 10 minutes preperfusion before TI (TIp). LV systolic pressure (62.4 % vs 93.6 % of each control value), developed pressure (57.0 % vs 95.3 %), and peak positive dp/dt (53.2 % vs 97.3 %) recovered better with reduced release of CK (458.7 vs 122.1 IU/g dwt) in the LFp group than in the LF group. ATP, creatine phosphate (CP) and lactate after reperfusion were the same in both the LF and the LFp group. Although there was no difference in recovery of LV function between the TI and TIp groups, recovery of CP decreased and 45Ca2+ uptake and release of CK were greater in the TI group. In hearts with low-flow ischemia and reperfusion, pimobendan enhanced recovery of LV function without deterioration of energy metabolism or Ca2+ overload. These results suggest that pimobendan may be beneficial for less severe ischemia causing myocardial stunning or hibernation but not for more severe ischemia resulting in irreversible injury.

Original languageEnglish
Pages (from-to)1165-1170
Number of pages6
JournalRespiration and Circulation
Volume48
Issue number11
Publication statusPublished - 2000

Fingerprint

Ischemia
Wounds and Injuries
Myocardial Stunning
Reperfusion
Phosphocreatine
Recovery of Function
pimobendan
Reperfusion Injury
Energy Metabolism
Lactic Acid
Myocardium
Adenosine Triphosphate
Blood Pressure
Pressure

Keywords

  • Ca sensitizer
  • Low-flow ischemia
  • Pimobendan

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Hasegawa, H., Tani, M., Honma, Y., Tamaki, K., Yamamura, K., Takayama, M., & Ebihara, Y. (2000). Ca2+ sensitizer, pimobendan, attenuates myocardial injury in low-flow ischemic but not in total ischemic hearts. Respiration and Circulation, 48(11), 1165-1170.

Ca2+ sensitizer, pimobendan, attenuates myocardial injury in low-flow ischemic but not in total ischemic hearts. / Hasegawa, H.; Tani, M.; Honma, Y.; Tamaki, K.; Yamamura, K.; Takayama, Michiyo; Ebihara, Y.

In: Respiration and Circulation, Vol. 48, No. 11, 2000, p. 1165-1170.

Research output: Contribution to journalArticle

Hasegawa, H, Tani, M, Honma, Y, Tamaki, K, Yamamura, K, Takayama, M & Ebihara, Y 2000, 'Ca2+ sensitizer, pimobendan, attenuates myocardial injury in low-flow ischemic but not in total ischemic hearts', Respiration and Circulation, vol. 48, no. 11, pp. 1165-1170.
Hasegawa, H. ; Tani, M. ; Honma, Y. ; Tamaki, K. ; Yamamura, K. ; Takayama, Michiyo ; Ebihara, Y. / Ca2+ sensitizer, pimobendan, attenuates myocardial injury in low-flow ischemic but not in total ischemic hearts. In: Respiration and Circulation. 2000 ; Vol. 48, No. 11. pp. 1165-1170.
@article{1f3fa9c8d9494586bcdcc7e729ea4d70,
title = "Ca2+ sensitizer, pimobendan, attenuates myocardial injury in low-flow ischemic but not in total ischemic hearts",
abstract = "Whether Ca2+ sensitizer is beneficial in cases of ischemic myocardium is still controversial. We examined the effect of pimobendan on ischemic-reperfusion injury. Isolated SD rat hearts were subjected to 30 minutes of low-flow ischemia (LF) or 25 minutes of total ischemia (TI) after 10 minutes of preperfusion, and were followed by 30 minutes of reperfusion. In another two groups we used 50μM of pimobendan during LF (LFp) or 10 minutes preperfusion before TI (TIp). LV systolic pressure (62.4 {\%} vs 93.6 {\%} of each control value), developed pressure (57.0 {\%} vs 95.3 {\%}), and peak positive dp/dt (53.2 {\%} vs 97.3 {\%}) recovered better with reduced release of CK (458.7 vs 122.1 IU/g dwt) in the LFp group than in the LF group. ATP, creatine phosphate (CP) and lactate after reperfusion were the same in both the LF and the LFp group. Although there was no difference in recovery of LV function between the TI and TIp groups, recovery of CP decreased and 45Ca2+ uptake and release of CK were greater in the TI group. In hearts with low-flow ischemia and reperfusion, pimobendan enhanced recovery of LV function without deterioration of energy metabolism or Ca2+ overload. These results suggest that pimobendan may be beneficial for less severe ischemia causing myocardial stunning or hibernation but not for more severe ischemia resulting in irreversible injury.",
keywords = "Ca sensitizer, Low-flow ischemia, Pimobendan",
author = "H. Hasegawa and M. Tani and Y. Honma and K. Tamaki and K. Yamamura and Michiyo Takayama and Y. Ebihara",
year = "2000",
language = "English",
volume = "48",
pages = "1165--1170",
journal = "Respiration and Circulation",
issn = "0452-3458",
publisher = "Igaku-Shoin Ltd",
number = "11",

}

TY - JOUR

T1 - Ca2+ sensitizer, pimobendan, attenuates myocardial injury in low-flow ischemic but not in total ischemic hearts

AU - Hasegawa, H.

AU - Tani, M.

AU - Honma, Y.

AU - Tamaki, K.

AU - Yamamura, K.

AU - Takayama, Michiyo

AU - Ebihara, Y.

PY - 2000

Y1 - 2000

N2 - Whether Ca2+ sensitizer is beneficial in cases of ischemic myocardium is still controversial. We examined the effect of pimobendan on ischemic-reperfusion injury. Isolated SD rat hearts were subjected to 30 minutes of low-flow ischemia (LF) or 25 minutes of total ischemia (TI) after 10 minutes of preperfusion, and were followed by 30 minutes of reperfusion. In another two groups we used 50μM of pimobendan during LF (LFp) or 10 minutes preperfusion before TI (TIp). LV systolic pressure (62.4 % vs 93.6 % of each control value), developed pressure (57.0 % vs 95.3 %), and peak positive dp/dt (53.2 % vs 97.3 %) recovered better with reduced release of CK (458.7 vs 122.1 IU/g dwt) in the LFp group than in the LF group. ATP, creatine phosphate (CP) and lactate after reperfusion were the same in both the LF and the LFp group. Although there was no difference in recovery of LV function between the TI and TIp groups, recovery of CP decreased and 45Ca2+ uptake and release of CK were greater in the TI group. In hearts with low-flow ischemia and reperfusion, pimobendan enhanced recovery of LV function without deterioration of energy metabolism or Ca2+ overload. These results suggest that pimobendan may be beneficial for less severe ischemia causing myocardial stunning or hibernation but not for more severe ischemia resulting in irreversible injury.

AB - Whether Ca2+ sensitizer is beneficial in cases of ischemic myocardium is still controversial. We examined the effect of pimobendan on ischemic-reperfusion injury. Isolated SD rat hearts were subjected to 30 minutes of low-flow ischemia (LF) or 25 minutes of total ischemia (TI) after 10 minutes of preperfusion, and were followed by 30 minutes of reperfusion. In another two groups we used 50μM of pimobendan during LF (LFp) or 10 minutes preperfusion before TI (TIp). LV systolic pressure (62.4 % vs 93.6 % of each control value), developed pressure (57.0 % vs 95.3 %), and peak positive dp/dt (53.2 % vs 97.3 %) recovered better with reduced release of CK (458.7 vs 122.1 IU/g dwt) in the LFp group than in the LF group. ATP, creatine phosphate (CP) and lactate after reperfusion were the same in both the LF and the LFp group. Although there was no difference in recovery of LV function between the TI and TIp groups, recovery of CP decreased and 45Ca2+ uptake and release of CK were greater in the TI group. In hearts with low-flow ischemia and reperfusion, pimobendan enhanced recovery of LV function without deterioration of energy metabolism or Ca2+ overload. These results suggest that pimobendan may be beneficial for less severe ischemia causing myocardial stunning or hibernation but not for more severe ischemia resulting in irreversible injury.

KW - Ca sensitizer

KW - Low-flow ischemia

KW - Pimobendan

UR - http://www.scopus.com/inward/record.url?scp=0033772817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033772817&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0033772817

VL - 48

SP - 1165

EP - 1170

JO - Respiration and Circulation

JF - Respiration and Circulation

SN - 0452-3458

IS - 11

ER -